Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
Name:
document(1).pdf
Size:
889.0Kb
Format:
PDF
Description:
Full text, Open Access article
Affiliation
Warwick Clinical Trials Unit, University of Warwick, CoventryIssue Date
2018-04-05
Metadata
Show full item recordAbstract
Twelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab. In this trial there will be a trade-off between a possible small decrease in disease-free survival (DFS) with 6-months and reduced cardiotoxicity and cost.Citation
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. 2018, 18(1): 391 BMC CancerJournal
BMC CancerDOI
10.1186/s12885-018-4307-8PubMed ID
29621991Type
ArticleLanguage
enISSN
1471-2407ae974a485f413a2113503eed53cd6c53
10.1186/s12885-018-4307-8
Scopus Count
Collections
Related articles
- Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
- Authors: Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, Shinkins B, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA
- Issue date: 2020 Aug
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
- Authors: Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA, PERSEPHONE Steering Committee and Trial Investigators
- Issue date: 2019 Jun 29
- Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials.
- Authors: Chen L, Zhou W, Hu X, Yi M, Ye C, Yao G
- Issue date: 2019 May
- One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
- Authors: Inno A, Barni S, Ghidini A, Zaniboni A, Petrelli F
- Issue date: 2019 Jan
- Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.
- Authors: Niraula S, Gyawali B
- Issue date: 2019 Jan